Leda Leme Talib

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12111959/publications.pdf

Version: 2024-02-01

687363 552781 45 823 13 26 citations h-index g-index papers 48 48 48 1707 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Differences in structural and functional default mode network connectivity in amyloid positive mild cognitive impairment: a longitudinal study. Neuroradiology, 2022, 64, 141-150.	2.2	2
2	Use of a Bayesian Network Model to predict psychiatric illness in individuals with â€at risk mental states†from a general population cohort. Neuroscience Letters, 2021, 770, 136358.	2.1	O
3	Senescence biomarkers in adults and elderly with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	O
4	Pattern of proteolytic processing of Amyloid Precursor Protein in Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	0
5	Differences in structural and functional DMN connectivity in amyloidâ€positive AMCI who converted to AD dementia. Alzheimer's and Dementia, 2020, 16, e041219.	0.8	O
6	Differences in functional connectivity in mild cognitive impairment for amyloidâ€positive versus SNAP. Alzheimer's and Dementia, 2020, 16, e042600.	0.8	0
7	Hippocampal connectivity may predict cholinesterase inhibitors response in mild Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042675.	0.8	0
8	Protein levels of APP, ADAM10 and BACE1 in aging adults with Down syndrome: Preliminary findings. Alzheimer's and Dementia, 2020, 16, e043190.	0.8	0
9	Platelet APPâ€ratio correlates with CSF levels of Aβ1â€42 in Alzheimer's disease patients. Alzheimer's and Dementia, 2020, 16, e043212.	0.8	O
10	Platelet APP levels from subjects with Alzheimer's disease and mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e043436.	0.8	0
11	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: A mass spectrometry study. Alzheimer's and Dementia, 2020, 16, e043519.	0.8	O
12	Alzheimer's disease: Donepezil effects on cholesterol and oxysterol plasma levels. Alzheimer's and Dementia, 2020, 16, e044144.	0.8	0
13	Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 963-972.	3.2	27
14	Glycogen synthase kinase- $3\hat{l}^2$ activity and cognitive functioning in patients with bipolar I disorder. European Neuropsychopharmacology, 2018, 28, 361-368.	0.7	4
15	Kynurenine is correlated with IL- $1\hat{1}^2$ in plasma of schizophrenia patients. Journal of Neural Transmission, 2018, 125, 869-873.	2.8	18
16	Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 501-507.	3.2	13
17	Cognitive Reserve Relates to Functional Network Efficiency in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 255.	3.4	30
18	Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 473-480.	3.7	25

#	Article	IF	CITATIONS
19	[P3–211]: LIPID METABOLITE PLASMA LEVELS AS BIOMARKERS OF EARLYâ€ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P1017.	0.8	O
20	[P3–212]: SPERMINE AS A POTENTIAL PERIPHERAL BIOMARKER OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1017.	0.8	1
21	[P1–233]: DONEPEZIL EFFECTS ON CHOLESTEROL AND OXYESTEROLS PLASMA LEVELS OF ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P333.	0.8	O
22	[P2–427]: DEPRESSION AND CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER's PATHOLOGY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P799.	0.8	0
23	[P3–133]: SYSTEMIC INFLAMMATION AND ALZHEIMER's DISEASE BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P985.	0.8	1
24	[P3–231]: PLASMATIC METABOLITES PREDICT CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1027.	0.8	0
25	[P3â€"296]: ARE CEREBROSPINAL FLUID BIOMARKERS A USEFUL TOOL TO DISCRIMINATE PATIENTS WITH MILD COGNITIVE IMPAIRMENT FROM HEALTHY INDIVIDUALS WITH NO COGNITIVE DETERIORATION?. Alzheimer's and Dementia, 2017, 13, P1056.	0.8	O
26	[P4â€"150]: COMORBIDITIES IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT WERE NOT RELATED TO AD PATHOLOGY ACCORDING TO CEREBROSPINAL FLUID BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P1315.	0.8	0
27	[P1–346]: EFFECTS OF AEROBIC EXERCISE ON PROGRESSION OF HIPPOCAMPAL VOLUME AND COGNITION IN AMNESTIC MILD COGNITIVE IMPAIRMENT DUE TO AD. Alzheimer's and Dementia, 2017, 13, P389.	0.8	2
28	Intranetwork and internetwork connectivity in patients with Alzheimer disease and the association with cerebrospinal fluid biomarker levels. Journal of Psychiatry and Neuroscience, 2017, 42, 366-377.	2.4	17
29	Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets. Journal of Alzheimer's Disease, 2016, 55, 1445-1451.	2.6	14
30	P1â€147: Donepezil Modulates Adam10 and Bace1 Expression in Platelets of Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P459.	0.8	0
31	P1â€404: APOE Genotype Modifies The Effects of Aerobic Training on Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P588.	0.8	2
32	Glycogen Synthase Kinase- $3\hat{l}^2$: Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. Neuropsychobiology, 2016, 73, 108-115.	1.9	5
33	Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons. Molecules, 2015, 20, 19878-19885.	3.8	14
34	Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects. Journal of Alzheimer's Disease, 2015, 46, 423-429.	2.6	71
35	Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease. NeuroMolecular Medicine, 2015, 17, 326-332.	3.4	50
36	The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects. PLoS ONE, 2015, 10, e0136141.	2.5	11

#	Article	IF	CITATIONS
37	P4-031: PLATELET APP RATIO IN AD PATIENTS TREATED WITH DONEPEZIL. , 2014, 10, P794-P794.		0
38	Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels. Current Alzheimer Research, 2014, 11, 799-805.	1.4	150
39	Antipsychotic drugs decrease iPLA 2 gene expression in schizophrenia. Schizophrenia Research, 2013, 147, 203-204.	2.0	7
40	Higher proportion of inactive $Gsk3\hat{l}^2$ in platelets of elderly patients with bipolar disorder: an effect of treatment?. Revista Brasileira De Psiquiatria, 2013, 35, 274-278.	1.7	10
41	Higher Serum sTNFR1 Level Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1305-1311.	2.6	85
42	Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment?. World Journal of Biological Psychiatry, 2011, 12, 216-222.	2.6	42
43	Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. Journal of Psychiatric Research, 2010, 44, 917-920.	3.1	49
44	Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World Journal of Biological Psychiatry, 2010, 11, 550-555.	2.6	56
45	Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World Journal of Biological Psychiatry, 2010, 11, 774-780.	2.6	116